Tylenol v. Advil: who'll come out on top?

Share this article:
Johnson & Johnson said it's returning some versions of children's and infant's Tylenol to stores after recalling millions of bottles earlier this year. How the brand fares may depend on the degree to which it can hold onto consumer loyalty.
Researchers from The Relational Capital Group and Princeton University surveyed 1,042 US consumers and found that the Tylenol brand slightly outpaces Pfizer's Advil in consumer loyalty (67% vs. 65% positive) and purchase intent (76% vs. 75% positive).

Respondents rated both brands equally well on such statements “is honest and trustworthy” and “acts with your best interest in mind.” These dimensions were shown to impact purchase intent and loyalty.  

Chris Malone, chief advisory officer of The Relational Capital Group, said consumers have interpreted J&J's quality control problems as “a temporary lapse in competence.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?